Quoin Pharmaceuticals (NASDAQ:QNRX) Director Dennis Langer Purchases 15,152 Shares

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Director Dennis Langer bought 15,152 shares of the firm’s stock in a transaction that occurred on Tuesday, October 14th. The stock was purchased at an average cost of $8.49 per share, with a total value of $128,640.48. Following the completion of the transaction, the director owned 15,153 shares in the company, valued at approximately $128,648.97. This trade represents a 1,515,200.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Quoin Pharmaceuticals Stock Up 8.7%

Shares of NASDAQ QNRX opened at $15.27 on Thursday. Quoin Pharmaceuticals, Ltd. Sponsored ADR has a 52-week low of $5.01 and a 52-week high of $54.95. The business has a 50-day moving average price of $8.17 and a 200 day moving average price of $7.96. The stock has a market cap of $9.01 million, a PE ratio of -0.37 and a beta of 1.66.

Quoin Pharmaceuticals (NASDAQ:QNRX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($6.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($6.83) by $0.55. Sell-side analysts anticipate that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -2.05 earnings per share for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Quoin Pharmaceuticals in a research report on Tuesday. One analyst has rated the stock with a Sell rating, According to MarketBeat, Quoin Pharmaceuticals presently has a consensus rating of “Sell”.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.